FOR IMMEDIATE RELEASE
Contact: Meico Whitlock
August 26, 2013, Washington, DC – The ADAP Crisis Task Force (ACTF) has reached a new pricing agreement with ViiV Healthcare for AIDS Drug Assistance Programs (ADAPs) for Tivicay® (dolutegravir) for the treatment of HIV-1 infected individuals. The agreed-upon ADAP direct purchase price for Tivicay®, negotiated between the ACTF and ViiV, is substantially lower than the wholesale acquisition cost (WAC), reflecting voluntary discounts that are also significantly below the mandated 340B pricing of the medication.
FOR IMMEDIATE RELEASE
Contact: Murray Penner
July 29, 2013, Washington, DC – As part of ongoing efforts by the ADAP Crisis Task Force (Task Force) and the pharmaceutical industry to address the continued need for access to HIV antiretroviral medicines through AIDS Drug Assistance Programs (ADAPs), the Task Force announced today that it has reached agreement with AbbVie, Gilead Sciences, Merck, and ViiV Healthcare to extend the voluntary discounts/rebates and price freezes available to all state ADAPs through December 31, 2014.
By Meico Whitlock, Senior Manager, Communications, NASTAD
In May at our 22nd Annual Meeting of state health department HIV and hepatitis program leaders in Washington, D.C., we had an opportunity to hear from federal and state leaders about Affordable Care Act (ACA) Implementation and its impact on HIV/AIDS and viral hepatitis program providers. Below is an interview with Amy Killelea, Senior Manager, Health Care Access at NASTAD and Maria Courogen, Director of Infectious Disease and Reproductive Health at the Washington State Department of Health who shared their highlights of the discussion. Continue reading
By Kathleen Sebelius, Secretary of Health and Human Services and Valerie Jarrett, Senior Advisor to the President
Cross-posted from AIDS.gov
Three years ago, President Obama announced an historic comprehensive plan to help turn the tide on HIV/AIDS in the United States: the National HIV/AIDS Strategy. The Strategy has given a new sense of direction, and purpose in our fight against HIV and AIDS.
Since the Strategy’s release, scientific developments have advanced our understanding of how to best fight HIV. We now understand that to prevent long-term complications of HIV, treatment is recommended for all adults and adolescents living with HIV in the United States. Continue reading